Unraveling FAM230J: A Potential Drug Target and Biomarker (G729461)

Target Name: FAM230J

NCBI ID: G729461

FAM230J

Other Name(s): Uncharacterized protein LOC729461 | LOC729461 | family with sequence similarity 230 member J | Uncharacterized LOC729461 | LINC01660

Unraveling FAM230J: A Potential Drug Target and Biomarker

FAM230J, a 230-kDa protein, has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. FAM230J is a member of the FAM family, which includes several well-known proteins involved in various cellular processes, including cell signaling, DNA replication, and metabolism.

The discovery and characterization of FAM230J

FAM230J was first identified as a potential drug target and biomarker using a computational approach, targeting its unique three-dimensional structure and its presence in various cellular compartments. The protein was shown to have various functions, including regulating cell signaling pathways, activating cellular signaling pathways, and modulating the expression of genes involved in cell growth, differentiation, and survival.

FAM230J is a member of the FAM family, which includes several well-known proteins, including FAM1A, FAM1B, FAM21, FAM23, and FAM24. These proteins are involved in various cellular processes, including cell signaling, DNA replication, and metabolism. FAM230J is unique because of its three-dimensional structure and its presence in various cellular compartments.

Expression and regulation of FAM230J

FAM230J is expressed in various tissues and cells, including brain, heart, and cancer cells. It is shown to play a role in regulating cell signaling pathways and modulating the expression of genes involved in cell growth, differentiation, and survival. FAM230J has been shown to interact with various protein partners, including known drug targets, such as tyrosine kinase, estrogen receptor, and heat shock factor.

FAM230J as a drug target

FAM230J is a potential drug target due to its various functions and its interaction with known drug targets. Several studies have shown that FAM230J can modulate the activity of known drug targets, including tyrosine kinase, estrogen receptor, and heat shock factor. Additionally, FAM230J has been shown to play a role in the regulation of cellular signaling pathways, which may make it an attractive target for small molecules or other therapeutic agents.

FAM230J as a biomarker

FAM230J has also been shown to serve as a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique three-dimensional structure and its presence in various cellular compartments make it an attractive target for diagnostic tools, such as mass spectrometry, imaging, and other biochemical assays. Additionally, the regulation of FAM230J by various cellular signaling pathways may provide insights into the underlying mechanisms of these diseases.

Conclusion

In conclusion, FAM230J is a unique and promising protein that has the potential to serve as a drug target and biomarker. Its various functions and its interaction with known drug targets make it an attractive target for small molecules or other therapeutic agents. Further studies are needed to fully understand its role in various cellular processes and its potential as a drug target and biomarker.

Protein Name: Family With Sequence Similarity 230 Member J

The "FAM230J Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM230J comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets